Why is "Proteasome inhibitor" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-05 03:35:26
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Proteasome inhibitors are drugs that block the action of proteasomes. Proteasomes are large proteins complexes that are used to break down other proteins. These inhibitors are being studied for the treatment of cancer. Drugs such as bortezomib, carfilzomib, and ixazomib are already approved for use in treating multiple myeloma and mantle cell lymphoma. They also work as immunosuppressants and inhibit bone resorption.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Established Proteasome Inhibitor Revitalizes CAR T-Cell Therapy in Multiple Myeloma - Pharmacy Times
-
VS-4718 enhances apoptosis induced by low-dose carfilzomib and overcomes carfilzomib resistance in PSMB5 -mutated proteasome inhibitor resistant multiple myeloma - nature.com
-
Rapaprotin, an Endopeptidase-Activated Proteasome Inhibitor that Induces 26S Disassembly - Wiley Online Library
-
With a €6.26M round, QLi5 doubles down on proteasome-based ADC payloads - European Biotechnology Magazine
-
Depletion of IgG-producing plasma cells in the colon by treatment of proteasome inhibitor ameliorates chronic DSS-induced colitis in mice - nature.com
-
Rapaprotin, an Endopeptidase-Activated Proteasome Inhibitor that Induces 26S Disassembly - Wiley Online Library
-
UM research reveals combination therapy enhances proteasome inhibitor-based immunotherapy for solid tumour cells - 澳門特別行政區政府入口網站
-
An Overview of Proteasome Inhibitor Therapy in Multiple Myeloma - CancerNetwork
-
Melatonin as a proteasome inhibitor. Is there any clinical evidence? - ScienceDirect.com
-
Mechanistic insights into proteasome inhibitor MG132 induced apoptosis in melanoma A375 cells - nature.com
-
Proteostasis Disruption by Proteasome Inhibitor MG132 and Propolin G Induces ER Stress- and Autophagy-Mediated Apoptosis in Breast Cancer - Wiley Online Library
-
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma - nature.com
-
The Proteasome Inhibitor Bortezomib Induces Neurogenesis and Toxicity in Rat Neural Stem Cells - Wiley
-
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL - nature.com
-
The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma - nature.com
-
Prolonged treatment with the proteasome inhibitor MG-132 induces apoptosis in PC12 rat pheochromocytoma cells - nature.com
-
Biosynthesis of lactacystin as a proteasome inhibitor - nature.com
-
Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research - nature.com
-
Proteasome Inhibitor Use in Myeloma - OncLive
-
Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties - nature.com
-
Selecting a Proteasome Inhibitor in Multiple Myeloma - OncLive
-
Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment - nature.com
-
Proteasome inhibitor bortezomib stabilizes and activates p53 in hematopoietic stem/progenitors and double-negative T cells in vivo - PNAS
-
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management | Blood Cancer Journal - nature.com
-
Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-κB activity in hepatocellular carcinoma - nature.com
-
Velcade: First in a New Class of Cancer Drug - Harvard Medical School
-
H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth - nature.com
-
Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance - PNAS
-
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal - nature.com
-
One-shot NMR analysis of microbial secretions identifies highly potent proteasome inhibitor - PNAS
-
Novel proteasome inhibitor combats malaria - nature.com
-
Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis - nature.com
-
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing - nature.com
-
The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1 - nature.com
-
Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma - Frontiers
-
Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models - nature.com
-
Proteasome inhibitor bortezomib stabilizes and activates p53 in hematopoietic stem/progenitors and double-negative T cells in vivo - PNAS
-
Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo - nature.com
-
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity - PNAS
-
Next-generation proteasome inhibitor approved in multiple myeloma - nature.com
-
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma - nature.com
-
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma - PNAS
-
Proteasome inhibitor unleashes three-pronged attack - nature.com
-
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma - nature.com
-
Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma - nature.com
-
Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response - nature.com
-
Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma - nature.com
-
Topical proteasome inhibitor promising for rosacea treatment - Healio
-
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism - nature.com
-
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia - nature.com
-
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe - ERS - European Respiratory Society
-
Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma - Frontiers
-
Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice - Wiley Online Library
-
MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression - nature.com
-
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy - CancerNetwork
-
The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor - 2 Minute Medicine
-
Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database - nature.com
-
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells - nature.com
-
Busulfan and cyclophosphamide for autologous stem cell transplantation in patients with multiple myeloma after proteasome inhibitor and/or immunomodulatory drug treatment - nature.com
-
Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78 - Frontiers
-
Oral proteasome inhibitor maintenance for multiple myeloma - The Lancet
-
Proteasome inhibitor MG-132 induces C6 glioma cell apoptosis via oxidative stress - nature.com
-
Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer - nature.com
-
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells - Frontiers
-
A novel proteasome inhibitor NPI-0052 as an anticancer therapy - nature.com
-
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib - nature.com
-
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review - nature.com
-
One Proteasome Inhibitor Tops Another in Relapsed Myeloma - medpagetoday.com
-
Proteasome inhibitor bortezomib for the treatment of multiple myeloma - nature.com
-
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis - nature.com
-
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma - nature.com
-
Proteasome inhibitors mechanism; source for design of newer therapeutic agents - nature.com
-
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM) - nature.com
-
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells - nature.com
-
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib - nature.com
-
18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib | Blood Cancer Journal - nature.com
-
Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer - nature.com
-
University of Macau (UM) study identifies novel drug combination - The Macau Post Daily
-
The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis - nature.com
-
Proteasome inhibition triggers the formation of TRAIL receptor 2 platforms for caspase-8 activation that accumulate in the cytosol - nature.com
-
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program - Wiley Online Library
-
Unprecedented PFS Improvement in Relapsed Multiple Myeloma - medpagetoday.com
-
Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells - nature.com
-
Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma - nature.com
-
Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo | Leukemia - nature.com
-
Ninlaro (ixazomib) for the Treatment of Multiple Myeloma - Clinical Trials Arena
-
Endogenous Bok is stable at the endoplasmic reticulum membrane and does not mediate proteasome inhibitor-induced apoptosis - Frontiers
-
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells - nature.com
-
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers - PNAS
-
Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1 - nature.com
-
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma - nature.com
-
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma - NEJM
-
The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia - Frontiers
-
Induction of apoptosis in human osteosarcoma Saos-2 cells by the proteasome inhibitor MG132 and the protective effect of pRb - nature.com
-
Bristol Myers' Abecma wins FDA nod in earlier multiple myeloma with updated boxed warning on secondary cancer - Fierce Pharma
-
Proteasome inhibitor‐induced apoptosis in human monocyte‐derived dendritic cells - Wiley Online Library
-
Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus Salinospora - Wiley Online Library
-
Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an 700 kDa Apaf-1 containing apoptosome complex - nature.com
-
Takeda takes on multiple myeloma outcomes study, as Ninlaro flounders - Fierce Biotech
-
Multiple Myeloma Market Size, Share & Trends Report, 2034 - Fortune Business Insights
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.